Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05685173 · ClinicalTrials.gov registry record · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
A Phase 1 study of B-cell Non-Hodgkins Lymphoma (B-NHL), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 20
- Study locations
NCT05685173: Recruiting Phase 1 study of B-cell Non-Hodgkins Lymphoma (B-NHL), sponsored by Regeneron Pharmaceuticals.
NCT05685173 is a Phase 1 study of B-cell Non-Hodgkins Lymphoma (B-NHL) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 91 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05685173, a Phase 1 study of B-cell Non-Hodgkins Lymphoma (B-NHL), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects) * To find out how well the study drugs work against relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs)
Primary Outcome
A DLT is defined as any non-haematologic and haematologic toxicity, as defined in the protocol, unless the event is clearly attributable to the underlying disease or to an extraneous cause (including concomitant medications).
Conditions Studied
Interventions
- DRUG Odronextamab
- DRUG REGN5837
Study Locations (20)
California
- City of Hope - Duarte
- University of California Los Angeles (UCLA) Medical Center - Santa Monica
Massachusetts
- Massachusetts General Hospital - Boston
- Harvard Medical School - Beth Israel Deaconess Medical Center - Boston
New York
- NYU Langone Health Perlmutter Cancer Center - New York
- Icahn School of Medicine at Mount Sinai - New York
Kentucky
- Norton Cancer Institute - Louisville
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Texas
- UT Southwestern - Dallas
Nouvelle-Aquitaine
- CHU de Bordeaux - Talence
Paris
- Hopital Saint Louis - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2029-05-16 |
| Phase | Phase 1 |
What NCT05685173 shows while recruiting
NCT05685173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% higher).
The record links to 1 condition, with B-cell Non-Hodgkins Lymphoma (B-NHL) appearing as the primary indexed condition, and to 2 interventions - of which Odronextamab is the first listed.
NCT05685173 names 20 study sites across 17 states, led by California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05685173 about?
NCT05685173 is a clinical study titled "A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas". The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2. The study is looking at sever...
What is the current status of trial NCT05685173?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2023-04-12. Estimated completion is 2029-05-16.
What conditions does trial NCT05685173 study?
This clinical trial studies the following conditions: B-cell Non-Hodgkins Lymphoma (B-NHL).
What interventions are being tested in trial NCT05685173?
The interventions under investigation include: Odronextamab (DRUG), REGN5837 (DRUG).
Who is sponsoring clinical trial NCT05685173?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05685173 being conducted?
This trial has 20 study locations across California, Kentucky, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05685173's enrollment target sits among peer trials
91 627th of 2000 higher than 1,373 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05847192 · 91 participants
Tau Networks in Psychotic Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI